Aurobindo Pharma gets FDA approval for generic equivalent of Xarelto
The anticoagulant drug, which has an estimated US market size of $447 million, is set to be launched in the first quarter of the 2025-26 fiscal.
13 April, 2025•2 min
0
13 April, 2025•2 min
0
Subscribe to read this story
We publish over 500 original, detailed stories every year on startups, corporates, stock markets and economic current affairs.
$99 for one year
SUBSCRIBE
Already have an account? Sign In
Not ready to subscribe? Sign up for a free account
We value our free readers. Read 100+ stories every year.
More in Business
Business
Many shades of grey in l’affaire Jane Street
The proprietary trading firm’s guilt is as obvious as its innocence, depending on who you ask. However, the truth often lies in the grey areas. Many answers are needed from both Jane Street and SEBI.
You may also like
Business
Has Aurobindo Pharma left its wild swings behind?
The Hyderabad-based generics maker has seen its stock scale all-time highs and lows in quick succession. With big plans in place and regulatory heat easing, its roller-coaster days may be over.
Business
Is Aurobindo Pharma the most underrated pharma company?
The Hyderabad-based generics maker is now India’s largest supplier of off-patent medicines to the US.